Solid Biosciences Inc · Q1 2021 earnings

Briefing

Solid Biosciences reported first quarter 2021 financial results and provided a business update.

Solid Biosciences reported a net loss of $16.9 million for the first quarter of 2021. The company's cash and cash equivalents were $268.5 million as of March 31, 2021, expected to fund operations into Q4 2022. Patient 8 in the IGNITE DMD trial experienced a serious adverse event.

• Patients 7 and 8 were dosed in the IGNITE-DMD Phase I/II clinical trial under a new clinical protocol and second-generation SGT-001 manufacturing process.
• Patient 8 experienced a serious adverse event.
• Long-term biopsy data from the ongoing IGNITE DMD trial demonstrated durable microdystrophin expression up to two years post dosing of SGT-001.
• The company ended Q1 with $268.5 million in cash, providing a cash runway into Q4 2022.

Headline financials

Revenue & EPS history

Solid Biosciences expects that its cash and cash equivalents will enable the company to fund its operating expenses and capital expenditures into the fourth quarter of 2022.